Indivior (NASDAQ:INDV) Shares Gap Up to $16.76

Indivior PLC (NASDAQ:INDV)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $16.76, but opened at $17.47. Indivior shares last traded at $17.33, with a volume of 30,577 shares.

Analyst Upgrades and Downgrades

Separately, Craig Hallum assumed coverage on shares of Indivior in a research report on Wednesday, April 3rd. They set a “buy” rating and a $37.00 price target for the company.

Indivior Price Performance

The business has a fifty day moving average of $19.27 and a 200-day moving average of $18.04. The firm has a market cap of $2.32 billion, a PE ratio of 1,676.00 and a beta of 0.63. The company has a current ratio of 0.92, a quick ratio of 0.74 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, April 25th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.01). Indivior had a return on equity of 842.72% and a net margin of 0.44%. The business had revenue of $284.00 million for the quarter, compared to analysts’ expectations of $300.00 million. As a group, research analysts predict that Indivior PLC will post 2 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Scopia Capital Management LP bought a new stake in shares of Indivior during the 3rd quarter valued at $191,743,000. Vanguard Group Inc. boosted its holdings in Indivior by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock worth $90,081,000 after purchasing an additional 52,836 shares during the last quarter. FMR LLC increased its position in Indivior by 53.5% during the third quarter. FMR LLC now owns 5,498,087 shares of the company’s stock valued at $119,339,000 after acquiring an additional 1,915,980 shares during the last quarter. Norges Bank purchased a new position in Indivior in the fourth quarter worth about $36,011,000. Finally, Toronto Dominion Bank grew its stake in shares of Indivior by 58.0% during the 1st quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock valued at $44,872,000 after purchasing an additional 769,000 shares during the period. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.